9M 2023 Financial Performance

9M 2023: APPENDIX Abilify LAI franchise ONCE-MONTHLY 400MG Abilify Maintena EVERY TWO MONTHS 960MG (aripiprazole) prolonged-release suspension for injection Abilify Asimtufii (aripiprazole) extended release suspension for injection Abilify LAI franchise revenue (Quarterly - DKKm) Abilify LAI franchise revenue (9M - DKKm) 1,050 40 900 750 600 450 300 150 3,000 +2% reported 2,000 1,000 +10% reported 0 0 Q3.20 Q3.21 Q3.22 Q3.23 9M 2020 9M 2021 9M 2022 9M 2023 United States Europe International Markets Unless otherwise stated, growth rates are at CER. Abilify Maintena was approved by FDA and by the EU Commission in February and November 2013, respectively. Abilify Asimtufii was approved by FDA April 2023. 1) Reported net sales of atypical LAIS. LAI: Long-acting injectable (LAI) Comments • • Grew 11% (+10% reported) to DKK 2.4bn in 9M 2023 Continued robust traction in value share achieving -21.5% share of the global LAI market¹) Abilify LAI franchise protected for several years: • 1-month formulation: Orange Book listed patents until March 2034. In RoW formulation patent expires October 2024 2-month formulation protected until mid-2030's

View entire presentation